52 related articles for article (PubMed ID: 31170467)
1. The hard protein corona of stealth liposomes is sparse.
Kristensen K; Engel TB; Stensballe A; Simonsen JB; Andresen TL
J Control Release; 2019 Aug; 307():1-15. PubMed ID: 31170467
[TBL] [Abstract][Full Text] [Related]
2. Differential cellular responses to FDA-approved nanomedicines: an exploration of albumin-based nanocarriers and liposomes in protein corona formation.
Putri AD; Hsu MJ; Han CL; Chao FC; Hsu CH; Lorenz CD; Hsieh CM
Nanoscale; 2023 Nov; 15(44):17825-17838. PubMed ID: 37850423
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the monocyte-targeting mechanisms of PEGylated cationic liposomes by investigating the biomolecular corona.
Münter R; Bak M; Thomsen ME; Parhamifar L; Stensballe A; Simonsen JB; Kristensen K; Andresen TL
Int J Pharm; 2024 May; 657():124129. PubMed ID: 38621615
[TBL] [Abstract][Full Text] [Related]
4. Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery.
Kim W; Ly NK; He Y; Li Y; Yuan Z; Yeo Y
Adv Drug Deliv Rev; 2023 Jan; 192():114635. PubMed ID: 36503885
[TBL] [Abstract][Full Text] [Related]
5. Interplay of protein corona and immune cells controls blood residency of liposomes.
Giulimondi F; Digiacomo L; Pozzi D; Palchetti S; Vulpis E; Capriotti AL; Chiozzi RZ; Laganà A; Amenitsch H; Masuelli L; Peruzzi G; Mahmoudi M; Screpanti I; Zingoni A; Caracciolo G
Nat Commun; 2019 Aug; 10(1):3686. PubMed ID: 31417080
[TBL] [Abstract][Full Text] [Related]
6. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer.
Palchetti S; Caputo D; Digiacomo L; Capriotti AL; Coppola R; Pozzi D; Caracciolo G
Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30650541
[TBL] [Abstract][Full Text] [Related]
7. Variations in metabolite profiles of serum coronas produced around PEGylated liposomal drugs by surface property.
Jang GJ; Jeong JY; Joung H; Han SY
Colloids Surf B Biointerfaces; 2023 Oct; 230():113488. PubMed ID: 37574616
[TBL] [Abstract][Full Text] [Related]
8. Effects of Surface IR783 Density on the In Vivo Behavior and Imaging Performance of Liposomes.
Long Q; Zhao X; Gao L; Liu M; Pan F; Gao X; Zhan C; Chen Y; Wang J; Qian J
Pharmaceutics; 2024 May; 16(6):. PubMed ID: 38931866
[No Abstract] [Full Text] [Related]
9. Functionalization of Liposomes with Hydrophilic Polymers Results in Macrophage Uptake Independent of the Protein Corona.
Weber C; Voigt M; Simon J; Danner AK; Frey H; Mailänder V; Helm M; Morsbach S; Landfester K
Biomacromolecules; 2019 Aug; 20(8):2989-2999. PubMed ID: 31268685
[TBL] [Abstract][Full Text] [Related]
10. Impact of Lipid Composition on Vesicle Protein Adsorption: A BSA Case Study.
Amărandi RM; Neamṭu A; Ştiufiuc RI; Marin L; Drăgoi B
ACS Omega; 2024 Apr; 9(16):17903-17918. PubMed ID: 38680315
[TBL] [Abstract][Full Text] [Related]
11. PEGylated nanoparticles interact with macrophages independently of immune response factors and trigger a non-phagocytic, low-inflammatory response.
Asoudeh M; Nguyen N; Raith M; Denman DS; Anozie UC; Mokhtarnejad M; Khomami B; Skotty KM; Isaac S; Gebhart T; Vaigneur L; Gelgie A; Dego OK; Freeman T; Beever J; Dalhaimer P
J Control Release; 2024 Feb; 366():282-296. PubMed ID: 38123071
[TBL] [Abstract][Full Text] [Related]
12. Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives.
Shen X; Pan D; Gong Q; Gu Z; Luo K
Bioact Mater; 2024 Feb; 32():445-472. PubMed ID: 37965242
[TBL] [Abstract][Full Text] [Related]
13. Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable".
Musicò A; Zenatelli R; Romano M; Zendrini A; Alacqua S; Tassoni S; Paolini L; Urbinati C; Rusnati M; Bergese P; Pomarico G; Radeghieri A
Nanoscale Adv; 2023 Sep; 5(18):4703-4717. PubMed ID: 37705771
[TBL] [Abstract][Full Text] [Related]
14. Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution.
Münter R; Christensen E; Andresen TL; Larsen JB
Mol Ther Methods Clin Dev; 2023 Jun; 29():450-459. PubMed ID: 37251983
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Gold Nanoshell-Based Photothermal Therapy Combined with Liposomal Doxorubicin in a Mouse Model of Colorectal Cancer.
Simón M; Jørgensen JT; Norregaard K; Henriksen JR; Clergeaud G; Andresen TL; Hansen AE; Kjaer A
Int J Nanomedicine; 2023; 18():829-841. PubMed ID: 36824412
[TBL] [Abstract][Full Text] [Related]
16. Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles.
Raith M; Nguyen N; Kauffman SJ; Kang N; Mays J; Dalhaimer P
J Control Release; 2023 Mar; 355():434-445. PubMed ID: 36758834
[TBL] [Abstract][Full Text] [Related]
17. Comment on "Optimal centrifugal isolating of liposome-protein complexes from human plasma" by L. Digiacomo, F. Giulimondi, A. L. Capriotti, S. Piovesana, C. M. Montone, R. Z. Chiozzi, A. Laganá, M. Mahmoudi, D. Pozzi and G. Caracciolo,
Münter R; Simonsen JB
Nanoscale Adv; 2022 Dec; 5(1):290-299. PubMed ID: 36605796
[TBL] [Abstract][Full Text] [Related]
18. Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles.
Thomsen MS; Johnsen KB; Kucharz K; Lauritzen M; Moos T
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297671
[TBL] [Abstract][Full Text] [Related]
19. Optimal centrifugal isolating of liposome-protein complexes from human plasma.
Digiacomo L; Giulimondi F; Capriotti AL; Piovesana S; Montone CM; Chiozzi RZ; Laganà A; Mahmoudi M; Pozzi D; Caracciolo G
Nanoscale Adv; 2021 Jun; 3(13):3824-3834. PubMed ID: 36133013
[TBL] [Abstract][Full Text] [Related]
20.
Singh N; Marets C; Boudon J; Millot N; Saviot L; Maurizi L
Nanoscale Adv; 2021 Mar; 3(5):1209-1229. PubMed ID: 36132858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
